A Rutgers scientist has invented an early treatment for COVID-19 to prevent severe complications and hospitalizations in patients with prediabetes and diabetes by increasing beneficial bacteria in the gut and reducing organisms that cause coronavirus. The treatment – created by researcher Liping Zhao – was given the Investigational New Drug status by the Food and Drug Administration and will start Phase 2a trial Feb. 8. While the treatment, NBT-NM108, does not target the coronavirus directly, it does help to create stable foundation for a healthy digestive tract. To read the full story.